Santen Pharmaceutical CoSNPHY 87 FCF Margin % is 22.79% as of Mar. 2026, which is 127% above its 10-year median of 10.02. GuruFocus rates SNPHY with a GF Score™ of 87/100 and a GF Value™ of $10.15 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 70.56% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHY) has a FCF Margin % of 22.79% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Santen Pharmaceutical Co and its competitors. This is 127% above median its historical median of 10.02. Over the past decade, Santen Pharmaceutical Co's FCF Margin % has ranged from 0.67 to 20.52. According to the industry distribution chart, Santen Pharmaceutical Co ranks #282 out of 958 companies in the Drug Manufacturers industry, placing it in the top 29.4%.
Is Santen Pharmaceutical Co's FCF Margin % too high?
Santen Pharmaceutical Co's current FCF Margin % of 22.79% is 127% above median its 10-year median of 10.02. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 20.52. The Drug Manufacturers industry median FCF Margin % is 2.51. Santen Pharmaceutical Co's value of 22.79% is 808% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #282 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Santen Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #282 out of 958 companies for FCF Margin %. This puts Santen Pharmaceutical Co in the upper half of its industry. The industry median FCF Margin % is 2.51. Santen Pharmaceutical Co's value of 22.79% is 808% above this benchmark. Historically, Santen Pharmaceutical Co's own FCF Margin % has ranged from 0.67 to 20.52 over the past decade. While the company's 10-year median is 10.02 vs. the industry median of 2.51, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current FCF Margin % of 22.79% is 808% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Santen Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current FCF Margin % is 22.79%, which is 127% above median its own 10-year median of 10.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.15, compared to a current price of $12.36 — trading 21.8% above its estimated fair value. The current FCF Margin % is 22.79%, which is 127% above median its 10-year median of 10.02 and 808% above the Drug Manufacturers industry median of 2.51. Santen Pharmaceutical Co's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current FCF Margin % is 22.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $12.36 is trading 21.8% above its estimated GF Value™ of $10.15.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHY:
FCF Margin %: 22.79% (127% above median its 10-year median of 10.02)
GF Value™: $10.15 vs. price of $12.36 (21.8% above fair value)
Industry Position: 808% above the Drug Manufacturers median (#282 of 958)
No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
87GF Score
Get the complete analysis for SNPHY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHY has been successfully added to your 
